Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate to severe atopic dermatitis: Results from the JADE REGIMEN phase 3 trial
Journal of the American Academy of Dermatology | Aug 20, 2021
Journal of the American Academy of Dermatology | Aug 20, 2021